1. Home
  2. REVB vs ARTL Comparison

REVB vs ARTL Comparison

Compare REVB & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • ARTL
  • Stock Information
  • Founded
  • REVB 2020
  • ARTL 2011
  • Country
  • REVB United States
  • ARTL United States
  • Employees
  • REVB N/A
  • ARTL N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • REVB Health Care
  • ARTL Health Care
  • Exchange
  • REVB Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • REVB 2.8M
  • ARTL 3.1M
  • IPO Year
  • REVB N/A
  • ARTL N/A
  • Fundamental
  • Price
  • REVB $2.92
  • ARTL $1.04
  • Analyst Decision
  • REVB
  • ARTL Strong Buy
  • Analyst Count
  • REVB 0
  • ARTL 2
  • Target Price
  • REVB N/A
  • ARTL $5.50
  • AVG Volume (30 Days)
  • REVB 147.3K
  • ARTL 1.2M
  • Earning Date
  • REVB 05-09-2025
  • ARTL 05-12-2025
  • Dividend Yield
  • REVB N/A
  • ARTL N/A
  • EPS Growth
  • REVB N/A
  • ARTL N/A
  • EPS
  • REVB N/A
  • ARTL N/A
  • Revenue
  • REVB N/A
  • ARTL N/A
  • Revenue This Year
  • REVB N/A
  • ARTL N/A
  • Revenue Next Year
  • REVB N/A
  • ARTL N/A
  • P/E Ratio
  • REVB N/A
  • ARTL N/A
  • Revenue Growth
  • REVB N/A
  • ARTL N/A
  • 52 Week Low
  • REVB $2.36
  • ARTL $0.82
  • 52 Week High
  • REVB $60.80
  • ARTL $1.59
  • Technical
  • Relative Strength Index (RSI)
  • REVB 45.77
  • ARTL 54.43
  • Support Level
  • REVB $2.76
  • ARTL $0.88
  • Resistance Level
  • REVB $3.62
  • ARTL $1.16
  • Average True Range (ATR)
  • REVB 0.41
  • ARTL 0.14
  • MACD
  • REVB 0.02
  • ARTL 0.02
  • Stochastic Oscillator
  • REVB 34.12
  • ARTL 37.93

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: